FDA supports science and research to help us better understand tobacco use and associated risks so that we can reduce the public health burden of tobacco in the United States.
Research programs and projects include, but are not limited to, the scientific fields of epidemiology, behavior, biology, medicine, economics, chemistry, engineering, toxicology, pharmacology, addiction, public health, communications, marketing, and statistics.
- Call for nominations: Nonvoting members for Tobacco Science Advisory Committee (TPSAC)
- Patterns of Tobacco Product Use in the United States: Transitions across Three Waves of the PATH Study (2013-2016). Tobacco Control 2020;29.
- PATH: Researchers Encouraged to Access Wave 3 (Part 1) Biomarker Restricted-Use File (BRUF) & Special Collection Wave 4.5: Youth Only Restricted-Use File (RUF)
- 2018 Tobacco Centers of Regulatory Science (TCORS) Awards
- Cost-Effectiveness Analysis of The Real Cost Campaign's Effect on Smoking Prevention, American Journal of Preventive Medicine
- Report on Tobacco Regulatory Science Research Program
- Find statistics about youth tobacco use from the most recent National Youth Tobacco Survey
- Find statistics about adult tobacco use from the most recent National Health Interview Survey
- Find recent CTP publications.
Stay current on FDA's tobacco regulatory science and research efforts, tobacco scientific publications and study findings, and research grants by subscribing to CTP's quarterly Spotlight on Science newsletter.
If you plan to study tobacco products that do not have marketing authorization or that do not comply with an applicable tobacco product standard, you may submit your proposed protocol to FDA for review. FDA intends to evaluate specific uses of investigational tobacco products on a case-by-case basis according to potential human subject protection concerns or other impacts on public health.
Generally, FDA does not recommend that investigators correspond with us about the use of investigational tobacco products in nonclinical studies as these are not ordinarily reviewed. You may refer to the draft guidance ‘Use of Investigational Tobacco Products’ for more information regarding how to submit your proposed use of an investigational tobacco product and how FDA intends to make enforcement decisions regarding the use of investigational tobacco products.
FDA understands that investigators may choose to obtain tobacco products directly from a tobacco product manufacturer with the sole intent to use the products for research investigations without commercializing the products. In such cases, FDA recommends that investigators add language to all product labels to indicate that these products are limited to investigational use, that study participants be instructed that the products may not be further distributed, and that study protocols include a plan to collect and account for all investigational tobacco products after the study has concluded.
- Read about the research goals of the Population Assessment of Tobacco and Health (PATH) Study, a collaboration between FDA and NIH, as well as availability of Restricted Use Files (RUF) and Public Use Files (PUF) for Waves 1 & 2.
- Learn about CTP's research priorities that build the science base behind FDA's authority to regulate tobacco products.
- Find out more about the Tobacco Regulatory Science Program (TRSP), FDA's partnership with NIH to foster tobacco regulatory research, including the Tobacco Centers of Regulatory Science (TCORS).
- Learn about FDA's collaboration with CDC on the National Youth Tobacco Survey.
- FDA Science Forum.
- Review information on Harmful and Potentially Harmful Constituents.
- Understand more about Modified Risk Tobacco Products and the rigorous standards in place to protect the public's health.
- Products, Ingredients and Components
- FDA's New Regulations for E-Cigarettes, Cigars, and All Other Tobacco Products
- FDA Safety Reporting Portal for Tobacco Products
- Connect with Us
- Tobacco Control Act